Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Functional interactions of fibrillar and oligomeric amyloid-β with alpha7 nicotinic receptors in Alzheimer's disease.

Lilja AM, Porras O, Storelli E, Nordberg A, Marutle A.

J Alzheimers Dis. 2011;23(2):335-47. doi: 10.3233/JAD-2010-101242.

PMID:
21116052
2.

Synapses, synaptic activity and intraneuronal abeta in Alzheimer's disease.

Tampellini D, Gouras GK.

Front Aging Neurosci. 2010 May 21;2. pii: 13. doi: 10.3389/fnagi.2010.00013. eCollection 2010.

3.

Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease.

Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, Långström B, Nordberg A.

Neurobiol Aging. 2012 Jan;33(1):198.e1-14. doi: 10.1016/j.neurobiolaging.2010.06.015. Epub 2010 Aug 4.

PMID:
20688420
4.

Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo.

Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C, Ahmed H, Almkvist O, Långström B, Nordberg A.

Neurobiol Aging. 2011 Dec;32(12):2320.e15-32. doi: 10.1016/j.neurobiolaging.2010.04.028. Epub 2010 Jun 9.

PMID:
20538374
5.

Pro: Can neuropathology really confirm the exact diagnosis?

Esiri MM.

Alzheimers Res Ther. 2010 May 7;2(2):10. doi: 10.1186/alzrt33.

6.

Con: Can neuropathology really confirm the exact diagnosis?

Jellinger KA.

Alzheimers Res Ther. 2010 May 7;2(2):11. doi: 10.1186/alzrt34.

7.

Cognition, glucose metabolism and amyloid burden in Alzheimer's disease.

Furst AJ, Rabinovici GD, Rostomian AH, Steed T, Alkalay A, Racine C, Miller BL, Jagust WJ.

Neurobiol Aging. 2012 Feb;33(2):215-25. doi: 10.1016/j.neurobiolaging.2010.03.011. Epub 2010 Apr 24.

8.

High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.

Forsberg A, Almkvist O, Engler H, Wall A, Långström B, Nordberg A.

Curr Alzheimer Res. 2010 Feb;7(1):56-66.

PMID:
20205671
9.

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Blennow K, Hampel H, Weiner M, Zetterberg H.

Nat Rev Neurol. 2010 Mar;6(3):131-44. doi: 10.1038/nrneurol.2010.4. Epub 2010 Feb 16. Review.

PMID:
20157306
10.

11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage.

Ly JV, Donnan GA, Villemagne VL, Zavala JA, Ma H, O'Keefe G, Gong SJ, Gunawan RM, Saunder T, Ackerman U, Tochon-Danguy H, Churilov L, Phan TG, Rowe CC.

Neurology. 2010 Feb 9;74(6):487-93. doi: 10.1212/WNL.0b013e3181cef7e3.

PMID:
20142615
11.

The use of PET in Alzheimer disease.

Nordberg A, Rinne JO, Kadir A, Långström B.

Nat Rev Neurol. 2010 Feb;6(2):78-87. doi: 10.1038/nrneurol.2009.217. Review.

PMID:
20139997
12.

The clinical use of structural MRI in Alzheimer disease.

Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM.

Nat Rev Neurol. 2010 Feb;6(2):67-77. doi: 10.1038/nrneurol.2009.215. Review.

13.

Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.

Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC.

Arch Neurol. 2009 Dec;66(12):1557-62. doi: 10.1001/archneurol.2009.279.

14.

Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation.

Schöll M, Almkvist O, Axelman K, Stefanova E, Wall A, Westman E, Långström B, Lannfelt L, Graff C, Nordberg A.

Neurobiol Aging. 2011 Aug;32(8):1388-99. doi: 10.1016/j.neurobiolaging.2009.08.016. Epub 2009 Sep 30.

PMID:
19796846
15.

Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.

Scheinin NM, Aalto S, Koikkalainen J, Lötjönen J, Karrasch M, Kemppainen N, Viitanen M, Någren K, Helin S, Scheinin M, Rinne JO.

Neurology. 2009 Oct 13;73(15):1186-92. doi: 10.1212/WNL.0b013e3181bacf1b. Epub 2009 Sep 2.

PMID:
19726751
16.

The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase.

Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H, Andreasen N, Nordberg A.

Neurobiol Aging. 2011 Jul;32(7):1236-48. doi: 10.1016/j.neurobiolaging.2009.07.015. Epub 2009 Aug 26.

PMID:
19713000
17.

Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease.

Ikonomovic MD, Wecker L, Abrahamson EE, Wuu J, Counts SE, Ginsberg SD, Mufson EJ, Dekosky ST.

Arch Neurol. 2009 May;66(5):646-51. doi: 10.1001/archneurol.2009.46.

18.

Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.

Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC.

Neurobiol Aging. 2009 Jul;30(7):1026-36. doi: 10.1016/j.neurobiolaging.2009.04.002. Epub 2009 Apr 18.

19.

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.

Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2009 May;132(Pt 5):1355-65. doi: 10.1093/brain/awp062. Epub 2009 Mar 31.

20.

Cognitive decline from estimated premorbid status predicts neurodegeneration in Alzheimer's disease.

Almkvist O, Tallberg IM.

Neuropsychology. 2009 Jan;23(1):117-24. doi: 10.1037/a0014074.

PMID:
19210039

Supplemental Content

Support Center